Q-omics provides the consensus-scored PCYOX1 profile across patient tissues and cancer cell-line models. PCYOX1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PCYOX1 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, PCYOX1 protein abundance shows 25,166 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRC, LUAD, and BRCA as cancer lineages where PCYOX1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCYOX1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCYOX1 survival associations across molecular data types. PCYOX1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCYOX1 RNA expression–survival associations across cancer types. High PCYOX1 expression shows unfavorable associations in BLCA, CESC and STAD, but favorable associations in KIRC, SARC and PRAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PCYOX1 RNA expression.
This table summarizes PCYOX1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 12. The strongest signals are observed in LUAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PCYOX1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCYOX1 shows lower tumor expression in LUAD, KICH, THCA, KIRC, KIRP and BRCA. The LUAD box plot shows higher PCYOX1 RNA expression in normal versus tumor tissue (log2 FC = −1.338, t-test p < 0.001).
This table shows molecular features associated with PCYOX1 in patient tissues and cancer cell lines. In patient samples, PCYOX1 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, PCYOX1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
